490 related articles for article (PubMed ID: 36843421)
1. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
[TBL] [Abstract][Full Text] [Related]
3. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
[TBL] [Abstract][Full Text] [Related]
4. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
5. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
[TBL] [Abstract][Full Text] [Related]
6. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma.
Gray S; de Liguori Carino N; Radhakrishna G; Lamarca A; Hubner RA; Valle JW; McNamara MG
Eur J Surg Oncol; 2022 Jun; 48(6):1198-1208. PubMed ID: 35264307
[TBL] [Abstract][Full Text] [Related]
7. Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.
Mavros MN; Moris D; Karanicolas PJ; Katz MHG; O'Reilly EM; Pawlik TM
JAMA Surg; 2021 Jul; 156(7):663-672. PubMed ID: 33787841
[TBL] [Abstract][Full Text] [Related]
8. Borderline resectable pancreatic cancer.
Hackert T; Ulrich A; Büchler MW
Cancer Lett; 2016 Jun; 375(2):231-237. PubMed ID: 26970276
[TBL] [Abstract][Full Text] [Related]
9. Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma.
Eid M; Ostřížková L; Kunovský L; Brančíková D; Kala Z; Hlavsa J; Janeček P; Kosíková I; Blažková M; Slabý O; Mayer J
Neoplasma; 2021 Jan; 68(1):1-9. PubMed ID: 32880468
[TBL] [Abstract][Full Text] [Related]
10. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Xie H; Liu J; Yin J; Ogden JR; Mahipal A; McWilliams RR; Truty MJ; Bekaii-Saab TS; Petersen GM; Jatoi A; Hubbard JM; Ma WW
Oncologist; 2020 Nov; 25(11):e1681-e1690. PubMed ID: 32663355
[TBL] [Abstract][Full Text] [Related]
11. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
12. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery.
Kitano Y; Inoue Y; Takeda T; Oba A; Ono Y; Sato T; Ito H; Ozaka M; Sasaki T; Sasahira N; Baba H; Takahashi Y
Ann Surg Oncol; 2023 Aug; 30(8):5093-5102. PubMed ID: 37140750
[TBL] [Abstract][Full Text] [Related]
13. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
[TBL] [Abstract][Full Text] [Related]
14. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.
Bouchart C; Navez J; Borbath I; Geboes K; Vandamme T; Closset J; Moretti L; Demetter P; Paesmans M; Van Laethem JL
BMC Cancer; 2023 Sep; 23(1):891. PubMed ID: 37735634
[TBL] [Abstract][Full Text] [Related]
15. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma.
Sakaguchi T; Satoi S; Yamamoto T; Yamaki S; Sekimoto M
Surg Today; 2020 Apr; 50(4):335-343. PubMed ID: 31993761
[TBL] [Abstract][Full Text] [Related]
16. Current Surgical Concepts and Future Perspectives in the Treatment of Borderline Resectable and Potentially Resectable Locally Advanced Pancreatic Cancer.
Karamarković AR; Juloski JT
Chirurgia (Bucur); 2022 Jun; 117(4):385-398. PubMed ID: 36049095
[TBL] [Abstract][Full Text] [Related]
17. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
Front Oncol; 2020; 10():41. PubMed ID: 32083002
[TBL] [Abstract][Full Text] [Related]
19. [The Clinical Efficacy of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Carcinoma--Report of Two Cases Treated by Curative Pancreatectomy with Portal Vein Resection after Neoadjuvant Chemotherapy].
Imamura T; Ikoma H; Morimura R; Hatakeyama T; Kosuga T; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Otsuji E
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2379-81. PubMed ID: 26805370
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015).
Yamada D; Kobayashi S; Takahashi H; Akita H; Yamada T; Asaoka T; Shimizu J; Takeda Y; Yokoyama S; Tsujie M; Tomokuni A; Tanemura M; Morimoto O; Murakami M; Kim Y; Nakahira S; Hama N; Sugimoto K; Hashimoto K; Doki Y; Eguchi H
Trials; 2021 Aug; 22(1):568. PubMed ID: 34446057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
